The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Predicting outcomes with WGS in multiple myeloma
Mehmet Samur, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the analysis of whole-genome sequencing (WGS) data from a 2009 study (NCT01191060) of multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone (RVD) alone or RVD followed by autologous stem cell transplantation (ASCT). A genomic scar score (GSS) was calculated for each member of the study cohort and used as a marker to identify clusters associated with specific outcomes. Patients with a low GSS score and a chromosome 9 gain had more positive outcomes when compared to the rest of the participants. This subgroup of patients was also found to have better post-ASCT outcomes. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
